证券代码：600488 证券简称：津药药业 编号：2025-037 津药药业股份有限公司 关于对参股公司增资暨关联交易的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： ●津药药业股份有限公司（以下简称"公司"或"津药药业"） 拟向参股公司江西百思康瑞药业有限公司（以下简称"江西百思康 瑞"）增资 2,040 万元。本次增资完成后，公司持股比例由 29.9946% 变为 29.9970%。 ●本次交易构成关联交易，但不构成《上市公司重大资产重组管 理办法》规定的重大资产重组。 ●根据《上海证券交易所股票上市规则》《公司章程》的规定， 此议案已经第九届董事会第十七次会议审议通过，在提交董事会审议 前，已经公司独立董事专门会议审议通过。本次交易无需提交股东大 会审议。 ●过去 12 个月公司与江西百思康瑞进行的日常关联交易累计金 额为 13,109.13 万元。公司未与其他关联人发生对外投资类型的关联 交易。 一、关联交易概述 （一）本次交易的基本情况 基于参股公司江西百思康瑞技术更新改造项目需要，为增强 ...

●本次交易构成关联交易，但不构成《上市公司重大资产重组管 理办法》规定的重大资产重组。 证券代码：600488 证券简称：津药药业 编号：2025-038 津药药业股份有限公司 关于控股子公司以自有资产抵押申请贷款暨关联交易公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： ●津药药业股份有限公司(以下简称"公司")控股子公司天津津 药环境科技有限公司（以下简称"环境科技"）拟以自有资产抵押继 续向天津医药集团财务有限公司（以下简称"财务公司"）申请贷款 1.35 亿元，贷款期限为三年。 ●根据《上海证券交易所股票上市规则》及《公司章程》的规定， 此议案已经第九届董事会第十七次会议审议通过，在提交董事会审议 前，已经公司独立董事专门会议审议通过。本次交易尚需提交股东大 会审议。 ●截至本次关联交易，过去 12 个月，公司及控股子公司与同一 关联人进行的交易共计 10 笔，累计发生额为 15,549.90 万元，已超 过公司最近一期经审计净资产的 5%。 一、关联交易概述 （一）本次交易的基本情况 公司于 ...

证券代码：600488 证券简称：津药药业 公告编号：2025-039 津药药业股份有限公司 关于召开2025年第二次临时股东大会的通知 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、 召开会议的基本情况 (一)股东大会类型和届次 2025年第二次临时股东大会 涉及融资融券、转融通业务、约定购回业务相关账户以及沪股通投资者 的投票，应按照《上海证券交易所上市公司自律监管指引第 1 号 — 规范运 作》等有关规定执行。 (四)现场会议召开的日期、时间和地点 召开的日期时间：2025 年 7 月 15 日 15 点 00 分 召开地点：天津开发区黄海路 221 号津药药业办公楼会议室 (五)网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自2025 年 7 月 15 日 至2025 年 7 月 15 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东大会召开当日的交易时间段，即 9:15-9:25,9:30-11:30，13:0 ...

津药药业股份有限公司 第九届监事会第十三次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 证券代码：600488 证券简称：津药药业 编号：2025-036 因生产经营及业务发展需要，公司子公司天津津药环境科技有限公 司（以下简称"环境科技"）拟以自有资产抵押向天津医药集团财务有限 公司（以下简称"财务公司"）申请三年期贷款 1.35 亿元。具体内容详 见上海证券交易所网站（www.sse.com.cn）同日披露的公告。 1 / 2 监事会认为：本次公司控股子公司环境科技拟以自有资产抵押向财 务公司申请三年期贷款 1.35 亿元，有利于解决生产经营及业务发展需要， 符合公司整体利益。公司对本议案的审议程序符合有关法律法规及《公 司章程》的规定，不存在损害公司及全体股东利益的情形，监事会同意 控股子公司以自有资产抵押申请贷款暨关联交易事项。 表决结果：同意票 3 票，反对票 0 票，弃权票 0 票。 特此公告。 津药药业股份有限公司（以下简称"公司"）第九届监事会第十三次 会议于 2025 年 6 月 25 ...

证券代码：600488 证券简称：津药药业 编号：2025-035 2.审议通过关于控股子公司以自有资产抵押申请贷款暨关联交易的议 案 公司于 2023 年 12 月 20 日经第九届董事会第三次会议、2024 年 1 月 10 日经 2024 年第一次临时股东大会审议通过"关于公司与天津医药集团财 务有限公司关联交易的议案"，公司与天津医药集团财务有限公司（以下简 称"财务公司"）签订《金融服务协议》，财务公司向公司提供金融服务总 额不超过 12.03 亿元（详见公司公告 2023-086#）； 公司于 2024 年 6 月 17 日经第九届董事会第八次会议公司审议通过"关 于控股子公司以自有资产抵押申请贷款暨关联交易的议案"，子公司天津津 药环境科技有限公司（以下简称"环境科技"）以自有资产抵押向财务公司 申请贷款 1.3 亿元，贷款期限为一年，贷款资金用于生产经营及业务发展需 要（详见公司公告 2024-031#）； 1/2 津药药业股份有限公司 第九届董事会第十七次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别 ...

Core Viewpoint - The recent penalty imposed by the State Administration for Market Regulation has exposed a hidden monopoly network in the pharmaceutical industry, with significant financial repercussions for the involved parties [1]. Group 1: Monopoly Scheme - A gathering organized by an individual named Guo in November 2021 led to a verbal agreement among four pharmaceutical companies to stop price competition and collectively raise prices [2]. - To evade regulatory scrutiny, the companies coordinated price hikes through Guo, using communication methods such as WeChat and phone calls [2]. Group 2: Price Surge - Following the agreement, the four companies collectively halted supply in January 2022, causing a severe market supply shortage [3]. - The price of the raw material dexamethasone skyrocketed from 8,000 yuan per kilogram to 13,800 yuan, marking a 72% increase [3]. - The price of dexamethasone injection surged from 0.35 yuan per unit to nearly 100 yuan, with some hospitals in Guangxi purchasing it at 60 yuan per unit, reflecting an alarming increase [3]. Group 3: Penalties and Legal Framework - The leniency policy in antitrust cases played a crucial role, with Tianyao Pharmaceutical receiving an 80% reduction in fines after self-reporting and providing key evidence, resulting in a total penalty of 69.19 million yuan [4]. - In contrast, Xianju Pharmaceutical faced a maximum fine of nearly 195 million yuan due to its failure to apply for leniency [4]. - All responsible individuals from the four companies were fined 600,000 yuan each [4]. Group 4: Regulatory Environment - The case is part of a broader trend, with multiple antitrust cases in the pharmaceutical sector being investigated in recent years, including those involving acetic acid and other raw materials [5]. - The regulatory framework has been strengthened with the introduction of the "Raw Material Drug Antitrust Guidelines" in 2021 and the "Drug Sector Antitrust Guidelines" set for 2025, establishing a comprehensive regulatory system [5]. - Antitrust enforcement is increasingly focused on essential sectors like pharmaceuticals, with new major cases leading to price reductions of up to 62% for involved drugs [5].

Core Viewpoint - Four pharmaceutical companies, including Tianjin Pharmaceutical Co., Ltd. (Tianjin Pharma), Zhejiang Xianju Pharmaceutical Co., Ltd. (Xianju Pharma), Jiangsu Lianhuan Pharmaceutical Co., Ltd. (Lianhuan Pharma), and Xi'an Guokang Ruijin Pharmaceutical Co., Ltd., were fined a total of 362 million yuan for price-fixing of dexamethasone raw materials, with Tianjin Pharma being penalized for the fourth time for similar monopolistic behavior [1][2][4]. Group 1: Companies Involved - Tianjin Pharma, Xianju Pharma, Lianhuan Pharma, and Xi'an Guokang Ruijin Pharma were involved in a price-fixing scheme for dexamethasone, leading to a significant increase in prices from 8,000 yuan/kg to 13,000 yuan/kg between February 2022 and March 2024 [2][4]. - Tianjin Pharma has a history of monopolistic practices, having been penalized multiple times since 2021 for various violations of antitrust laws [4][5]. - Lianhuan Pharma's fine represents 72.53% of its net profit, significantly impacting its financial performance [6][8]. Group 2: Regulatory Actions - The Tianjin Municipal Market Supervision Administration imposed fines based on the companies' previous year's sales, totaling 355 million yuan, along with confiscation of illegal gains [2][7]. - The regulatory body emphasized the importance of maintaining fair competition in the pharmaceutical sector and indicated a commitment to stricter enforcement of antitrust laws [2][4]. - Lianhuan Pharma has submitted a hearing request to reduce its penalties, but the regulatory authority rejected its arguments, affirming the validity of the evidence against the company [7]. Group 3: Financial Impact - Lianhuan Pharma reported revenues of 2.174 billion yuan and 2.160 billion yuan for 2023 and 2024, respectively, with net profits declining by 4.5% and 37.66% [6][8]. - The fine imposed on Lianhuan Pharma will reduce its net profit for 2025 by approximately 61.04 million yuan [8]. - Tianjin Pharma's market influence is significant, with a strong presence in the domestic market for steroid hormone raw materials [5].

Core Viewpoint - The National Market Supervision Administration has imposed a total fine of 355 million yuan on four pharmaceutical companies for colluding to raise the price of dexamethasone phosphate raw materials, which saw a price increase of up to 282 times [1] Group 1: Companies Involved - Four companies involved in the price-fixing scheme include Tianjin Pharmaceutical Co., Jiangsu Lianhuan Pharmaceutical Co., Xi'an Guokang Ruijin Pharmaceutical Co., and Zhejiang Xianju Pharmaceutical Co. [1] - The organizer of the collusion, identified as Guo, was fined the maximum amount of 5 million yuan, while four responsible individuals from the companies were fined 600,000 yuan each [1] Group 2: Price Increases - Dexamethasone phosphate raw material prices were raised significantly, with Tianjin Pharmaceutical increasing prices from 9,000 yuan/kg to 13,800 yuan/kg, and Xi'an Guokang Ruijin raising prices from 7,900 yuan/kg to between 10,000 and 38,000 yuan/kg [1] - Zhejiang Xianju Pharmaceutical raised prices from 8,200 yuan/kg to 10,000 yuan/kg, while Jiangsu Lianhuan increased prices from 7,800 yuan/kg to 15,000 yuan/kg [1] Group 3: Market Impact - The collusion led to a severe market supply shortage, with the price of dexamethasone phosphate injection skyrocketing from 0.35 yuan per dose to 98.76 yuan per dose, marking a staggering increase of 282 times [1] - As of March 7, 2024, the monopolistic pricing of dexamethasone phosphate raw materials was still being enforced [1] Group 4: Legal Consequences - The total illegal gains from the price-fixing scheme were calculated as follows: Tianjin Pharmaceutical Co. 42,764,400 yuan, Zhejiang Xianju Pharmaceutical Co. 23,746,680 yuan, Xi'an Guokang Ruijin Pharmaceutical Co. 24,763,156 yuan, and Jiangsu Lianhuan Pharmaceutical Co. 17,899,200 yuan [1] - The fines imposed on the four companies amounted to 355 million yuan, which includes the confiscation of illegal gains and an additional penalty of 8% of the previous year's sales [1]

Core Viewpoint - Tianjin Pharmaceutical Industry (津药药业) has repeatedly violated antitrust laws, resulting in significant administrative penalties totaling 362 million yuan for price-fixing agreements with other companies in the industry [1][2][10]. Summary by Relevant Sections Antitrust Violations and Penalties - On June 13, the State Administration for Market Regulation announced penalties against Tianjin Pharmaceutical and three other companies for engaging in price-fixing agreements, with a total fine of 362 million yuan [1]. - The company has been penalized a total of 171 million yuan over four antitrust violations in the past four years [2][10]. Price Increases - On February 21, 2022, Tianjin Pharmaceutical raised the price of dexamethasone phosphate raw materials from 9,000 yuan per kilogram to 13,800 yuan per kilogram, an increase of over 53% [4][5]. Management Accountability - Liu Xin, the general manager of Tianjin Pharmaceutical, was fined 600,000 yuan for his role in the antitrust violations [5][6]. - Following the penalties, Liu Xin was no longer listed among the company's executives after a board reshuffle in September 2023 [1][6]. Previous Violations - Since April 2021, Tianjin Pharmaceutical has faced three additional penalties for violating antitrust laws, indicating a pattern of non-compliance [1][7].

Group 1 - The company involved is Tianjin Pharmaceutical Co., Ltd., which is engaged in the production of pharmaceuticals, veterinary drugs, cosmetics, and food additives [1][2] - The company and its representatives are accused of violating the Anti-Monopoly Law by engaging in monopolistic behavior with competitors [2][3] - The investigation was initiated based on a tip-off from the State Administration for Market Regulation, leading to a formal inquiry into the company's practices [2][3] Group 2 - The primary product involved is Dexamethasone Sodium Phosphate, a key raw material for producing Dexamethasone injection, which is used for treating various inflammatory diseases and has been included in COVID-19 treatment protocols [4][6] - The company, along with three other competitors, was found to have a direct competitive relationship in the production and sale of this raw material [6][7] Group 3 - Evidence indicates that the company participated in a price-fixing agreement for Dexamethasone Sodium Phosphate, which included a meeting on November 20, 2021, to discuss price increases and the cessation of price competition [7][8] - The company raised the price of Dexamethasone Sodium Phosphate from 9,000 yuan per kilogram to 13,800 yuan per kilogram in February 2022, following the agreement [7][9] Group 4 - The company reported illegal earnings of 42,764,400 yuan from the price-fixing activities [9] - Following the investigation, the company applied for leniency and began to lower prices in June 2024, indicating a willingness to rectify its actions [10][13] Group 5 - The administrative penalties imposed include the confiscation of illegal earnings and a fine based on the company's sales revenue, with a total penalty amounting to 69,192,350.36 yuan [13][14] - The company's general manager, Liu Xin, was also fined 600,000 yuan for personal responsibility in the monopolistic practices [15]